Mizuho Raises AMGN Price Target to $352 Amid Cautious Optimism

Amgen's (AMGN) stock has received an update from Mizuho analysts who maintained their Neutral rating on the biotech company. The price target for AMGN has been increased to $352, up 16.17% from its previous target of $303.

The raise in price target suggests that analysts see room for growth in Amgen's stock, but maintain a cautious optimism due to the current valuation relative to its growth prospects. The company's market capitalization stands at approximately $226.88 billion, making it a significant player in the healthcare sector.

According to GuruFocus' GF Value™ metric, AMGN is currently 14.9% overvalued at its current price of $419.38, with an intrinsic value of $364.93. This indicates that investors may be paying a premium for the stock compared to its intrinsic worth.